

(Company No : 680889-W)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2013

	Current Quarter Ended 30.9.2013 (Unaudited) RM'000	Corresponding Quarter Ended 30.9.2012 (Unaudited) RM'000	Current Year-To-Date Ended 30.9.2013 (Unaudited) RM'000	Corresponding Year-To-Date Ended 30.9.2012 (Unaudited) RM'000
Revenue	8,980	8,174	25,707	24,274
Operating profit	3,174	2,798	8,878	7,966
Operating expenses	(1,860)	(2,008)	(5,826)	(6,002)
Finance costs	(87)	(106)	(258)	(327)
Profit before taxation	1,227	684	2,794	1,637
Tax expense	(185)	(173)	(439)	(467)
Profit after taxation	1,042	511	2,355	1,170
Other comprehensive income, net of tax <i>Items that may be reclassified subsequently to profit or loss</i>				
Foreign currency translation	7	2	16	8
Total comprehensive income	1,049	513	2,371	1,178
Profit after taxation attributable to Owners of the Company:	1,042	511	2,355	1,170
Total comprehensive income attributable to Owners of the Company:	1,049	513	2,371	1,178
Earnings per share (sen) attributable to Owners of the Company:				
- Basic	0.70	0.34	1.58	0.78

Note:-

The above condensed consolidated statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 31 December 2012 and the accompanying explanatory notes attached to the interim financial statements.

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 SEPTEMBER 2013

	As At Current Year Quarter 30.9.2013 (Unaudited) RM'000	As At Financial Year End 31.12.2012 (Audited) RM'000
ASSETS		
Non - current assets		
Property, plant and equipment	15,977	16,379
Product development expenditure	135	321
Goodwill	58	58
	<u>16,170</u>	<u>16,758</u>
Current assets		
Inventories	12,772	9,244
Trade receivables	6,418	7,171
Other receivables, deposits and prepayments	637	407
Tax refundable	90	107
Fixed and short term deposits with licensed banks	3,230	2,286
Cash and bank balances with licensed banks and other financial institution	5,468	5,284
	<u>28,615</u>	<u>24,499</u>
TOTAL ASSETS	<u>44,785</u>	<u>41,257</u>
EQUITY AND LIABILITIES		
Equity		
Share capital	14,939	14,939
Share premium	3,520	3,520
Treasury shares	(14)	(12)
Retained profits	18,285	16,826
Revaluation reserves	3,177	3,177
Merger deficit	(8,397)	(8,397)
Currency translation reserve	(19)	(35)
	<u>31,491</u>	<u>30,018</u>
Non-current liabilities		
Deferred taxation	523	524
Hire purchase payables	28	84
Term loans	4,435	4,849
	<u>4,986</u>	<u>5,457</u>
Current Liabilities		
Trade payables	4,580	3,157
Bill payable	1,188	1,247
Other payables and accruals	1,004	716
Amount owing to directors	5	2
Hire purchase payables	84	133
Term loans	548	527
Dividend payable	896	-
Provision for taxation	3	-
	<u>8,308</u>	<u>5,782</u>
TOTAL LIABILITIES	<u>13,294</u>	<u>11,239</u>
TOTAL EQUITY AND LIABILITIES	<u>44,785</u>	<u>41,257</u>
Net assets per share (RM) attributable to owners of the Company	<u>0.21</u>	<u>0.20</u>

Note:-

The above condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 31 December 2012 and the accompanying explanatory notes attached to the interim financial statements.

The net assets per share attributable to owners of the Company is calculated based on net assets value and the issued paid up share capital of 149,320,500 shares (149,330,500 shares - 2012) excluding treasury shares.

(Company No : 680889-H)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2013

	←-----			Non-distributable			-----→		Distributable	Total Equity RM'000
	Share Capital RM'000	Share Premium RM'000	Treasury Shares RM'000	Fair Value Reserve RM'000	Revaluation Reserves RM'000	Merger Deficit RM'000	Currency Translation Reserve RM'000	Retained Profits RM'000		
Quarter ended 30 September 2013 (Unaudited)										
Balance at 1 January 2013	14,939	3,520	(12)	-	3,177	(8,397)	(35)	16,826	30,018	
Profit after taxation for the financial period	-	-	-	-	-	-	-	2,355	2,355	
Other comprehensive income for the financial period, net of tax:										
- Foreign currency translation	-	-	-	-	-	-	16	-	16	
Total comprehensive income for the financial period	-	-	-	-	-	-	16	2,355	2,371	
Purchase of own shares	-	-	(2)	-	-	-	-	-	(2)	
Interim dividend of RM0.008 per ordinary shares of RM0.10 each less income tax of 25% in respect of the financial year ending 31 December 2013	-	-	-	-	-	-	-	(896)	(896)	
Balance at 30 September 2013	14,939	3,520	(14)	-	3,177	(8,397)	(19)	18,285	31,491	

Quarter ended 30 September 2012
(Unaudited)

Balance at 1 January 2012	14,939	3,520	-	*	3,178	(8,397)	(29)	16,305	29,516
Profit after taxation for the financial period	-	-	-	-	-	-	-	1,170	1,170
Other comprehensive income for the financial period, net of tax:									
- Foreign currency translation	-	-	-	-	-	-	8	-	8
- Fair value changes of available-for-sale financial asset	-	-	-	**	-	-	-	-	-
Total comprehensive income for the financial period	-	-	-	-	-	-	8	1,170	1,178
Purchase of own shares	-	-	(2)	-	-	-	-	-	(2)
Balance at 30 September 2012	14,939	3,520	(2)	-	3,178	(8,397)	(21)	17,475	30,692

Note:-

- * RM650
- ** (RM650)

The above condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 31 December 2012 and the accompanying explanatory notes attached to the interim financial statements.

(Company No : 680889-B)

SUNZEN BIOTECH BERHAD
(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2013

	Current Year To Date Ended 30.9.2013 (Unaudited) RM'000	Corresponding Year To Date Ended 30.9.2012 (Unaudited) RM'000
Cash flows from/(for) operating activities		
Profit before taxation	2,794	1,637
Adjustments for:-		
Amortisation of product development expenditure	186	184
Depreciation of property, plant and equipment	363	467
Interest expense	245	309
Plant and equipment written off	-	3
Inventories written off	62	116
Product development expenditure written off	-	77
Gain on disposal of plant and equipment	-	(1)
Gain on disposal of quoted shares	-	(2)
Interest income	(67)	(72)
Unrealised gain on foreign exchange	(62)	(119)
Operating profit before working capital changes	<u>3,521</u>	<u>2,599</u>
Increase in inventories	(3,590)	(1,626)
Decrease/(Increase) in trade and other receivables	582	(123)
Increase/(Decrease) in trade and other payables	<u>1,694</u>	<u>(772)</u>
Cash from operations	<u>2,207</u>	<u>78</u>
Net tax paid	(420)	(272)
Interest paid	(247)	(311)
Net cash from/(for) operating activities	<u>1,540</u>	<u>(505)</u>
Cash flows from/(for) investing activities		
Interest received	67	72
Purchase of property, plant and equipment	(29)	(738)
Proceeds from disposal of plant and equipment	-	1
Proceeds from disposal of quoted shares	-	6
Net cash from/(for) investing activities	<u>38</u>	<u>(659)</u>
Cash flows from/(for) financing activities		
Repayment of term loans	(391)	(370)
Advances from directors	3	-
Repayment of hire purchase obligations	(105)	(100)
Treasury shares	(2)	(2)
Net cash for financing activities	<u>(495)</u>	<u>(472)</u>
Net increase/(decrease) in cash and cash equivalents	1,083	(1,636)
Cash and cash equivalents at beginning of the financial period	7,570	10,375
Foreign exchange difference	45	8
Cash and cash equivalents at end of the financial period	<u>8,698</u>	<u>8,747</u>
Cash and cash equivalents comprise:		
Fixed and short term deposits with licensed banks	3,230	3,360
Cash and bank balances with licensed banks and other financial institution	<u>5,468</u>	<u>5,387</u>
	<u>8,698</u>	<u>8,747</u>

Note:-

The above condensed consolidated statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 31 December 2012 and the accompanying explanatory notes attached to the interim financial statements.

SUNZEN BIOTECH BERHAD

(Company No: 680889-W)
(Incorporated in Malaysia)

NOTES TO THE INTERIM STATEMENTS FOR THE FINANCIAL PERIOD ENDED 30 SEPTEMBER 2013

A. NOTES PURSUANT TO THE MALAYSIAN FINANCIAL REPORTING STANDARD 134 (MFRS 134): INTERIM FINANCIAL REPORTING

A1. Basis of reporting preparation

The unaudited interim financial statements have been prepared in accordance with the Malaysian Financial Reporting Standards (“MFRSs”) 134: “Interim Financial Reporting” issued by the Malaysian Accounting Standards Board (“MASB”) and Chapter 9, Part K of the Listing Requirements of Bursa Malaysia Securities Berhad (“Bursa Securities”) for the ACE Market (“ACE LR”). The unaudited interim financial statements should be read in conjunction with the audited annual financial statements of the Group for the financial year ended 31 December 2012.

The following MFRSs and Amendments to MFRSs applicable to the Group have been adopted with effect from 1 January 2013.

- MFRS 10 Consolidated Financial Statements
- MFRS 11 Joint Arrangements
- MFRS 12 Disclosure of Interests in Other Entities
- MFRS 13 Fair Value Measurement
- MFRS 119 Employee Benefits (2011)
- MFRS 127 Separate Financial Statements (2011)
- MFRS 128 Investment in Associates and Joint Ventures (2011)
- Amendments to MFRS 7: Financial Instruments: Disclosures - Offsetting Financial Assets and Financial Liabilities
- Amendments to MFRS 1: First-time Adoption of Malaysian Financial Reporting Standards (Annual Improvements 2009-2011 Cycle)
- Amendments to MFRS 101: Presentation of Financial Statements (Annual Improvements 2009-2011 Cycle)
- Amendments to MFRS 116: Property, Plant and Equipment (Annual Improvements 2009-2011 Cycle)
- Amendments to MFRS 132: Financial Instruments: Presentation (Annual Improvements 2009-2011 Cycle)
- Amendments to MFRS 134: Interim Financial Reporting (Annual Improvements 2009-2011 Cycle)
- Amendments to MFRS 10: Consolidated Financial Statements: Transition Guidance
- Amendments to MFRS 11: Joint Arrangements: Transition Guidance
- Amendments to MFRS 12: Disclosure of Interests in Other Entities: Transition Guidance

The adoption of the above standards and amendments is not expected to have any material financial impact to the financial statements of the Group.

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

A1. Basis of reporting preparation (*Cont'd*)

The following revised MFRSs and Amendments to MFRSs applicable to the Group, have been issued by the MASB are not yet effective for adoption by the Group.

Amendments effective for annual periods beginning on or after 1 January 2014

Amendments to MFRS 10: Consolidated Financial Statements: Investment Entities

Amendments to MFRS 12: Disclosure of Interests in Other Entities: Investment Entities

Amendments to MFRS 127: Separate Financial Statements (2011): Investment Entities

Amendments to MFRS 132: Financial Instruments: Presentation - Offsetting Financial Assets and Financial Liabilities

Amendments to MFRS 136: Recoverable Amount Disclosures for Non-Financial Assets

Amendments to MFRS 139: Novation of Derivatives and Continuation of Hedge Accounting

MFRSs and Amendments effective for annual periods beginning on or after 1 January 2015

MFRS 9 Financial Instruments (2009)

MFRS 9 Financial Instruments (2010)

Amendments to MFRS 7 Financial Instruments: Disclosures - Mandatory Effective Date of MFRS 9 and Transition Disclosures

The adoption of the above standards and amendments is not expected to have any material financial impact to the Group upon their first adoption.

A2. Auditors' report on preceding annual financial statements

The audited financial statements of the Company and its subsidiaries for the FYE 31 December 2012 were not subjected to any qualification.

A3. Seasonal or cyclical factors

The principal business operations of the Group were not significantly affected by seasonal or cyclical factors during the current quarter under review.

A4. Items of unusual nature and amount

There were no items affecting assets, liabilities, equity, net income or cash flows that were unusual because of their nature, size or incidence during the current quarter under review.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

A5. Material changes in estimates

There were no material changes in estimates of amounts reported that will have a material effect in the current quarter under review.

A6. Issuances, cancellations, repurchase, resale and repayments of debt and equity securities

There were no issuances, cancellations, resale and repayments of debt and equity securities during the current quarter under review. On 3 September 2013, the Company repurchased 10,000 of its issued shares from the open market of Bursa Securities at RM0.23 each for total cost of RM2,343. As at 30 September 2013, the total number of shares repurchased and retained as treasury shares was 70,000 for total cost of RM14,560.

A7. Dividend paid

No dividend paid during the quarter under review.

A8. Segmental information

Segmental revenue on the basis of geographical market is as follows:

Geographical Market	Current Year-To-Date Ended 30 September 2013 RM'000	Corresponding Year-To-Date Ended 30 September 2012 RM'000
Asia other than Malaysia	6,000	4,419
Middle East	523	182
Africa	48	57
Total export	6,571	4,658
Malaysia	19,136	19,616
Total revenue	25,707	24,274

Export sales posted a 41.07% increase in revenue as compared to the corresponding year-to-date, which was attributed to the growing sales demand of Orgacids in countries such as Vietnam, China and Iran and the same for companion animal products to Singapore. Orgacids and companion animal products contributed to export sales of 66.34% and 23.77%, respectively, for the current year-to-date.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

A9. Valuation of property, plant and equipment

The valuation of the Group's freehold lands and buildings has been brought forward without any amendments from the annual financial statements for the FYE 31 December 2012.

A10. Capital commitments

As at the end of reporting period, there were no outstanding capital commitments not provided for in the financial statements.

A11. Material subsequent event

There were no material events subsequent to the end of the current quarter that have not been reflected in the financial statements, which are likely to substantially affect the current quarter results under review.

A12. Changes in the Composition of the Group

There were no changes in the composition of the Group in the current quarter under review.

A13. Contingent Liabilities

Save for the corporate guarantee granted by the Company in favour of financial institutions for Islamic banking facilities extended to a subsidiary amounting to **RM17,131,000**, neither the Company nor its subsidiaries have any contingent liabilities at the end of the reporting period, which upon becoming enforceable, may have a material effect on the financial position of the Group.

The corporate guarantee forms part of the securities for the following banking facilities made available to a subsidiary company.

Islamic Banking Facility	Corporate Guarantee RM'000	Limit RM'000	Outstanding Balance
			As At 30 September 2013 RM'000
Bank overdraft	500	500	156
Trade line	6,000	6,000	1,188
Term loans	10,631	6,465	4,983
Total	17,131	12,965	6,327

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

B. ADDITIONAL INFORMATION REQUIRED UNDER THE ACE LR

B1. Review of performance of the Company and its principal subsidiaries for the current quarter and financial year-to-date

	Current Quarter Ended 30 September 2013 RM'000	Corresponding Quarter Ended 30 September 2012 RM'000	Current Year-To-Date Ended 30 September 2013 RM'000	Corresponding Year-To-Date Ended 30 September 2012 RM'000
Revenue	8,980	8,174	25,707	24,274
Profit before taxation ("PBT")	1,227	684	2,794	1,637

Group's revenue for the current quarter reported a 9.86% increase compared to the previous year's corresponding quarter, which was mainly contributed by companion animal products sales for both local and Singapore markets and also sales demand of Orgacids from Vietnam and China.

Group's PBT increased significantly by 79.39% quarter-on-quarter mainly due to improved sales performance of companion animal products and Orgacids. Lower product development expenditure and higher gain on foreign exchange in the current quarter also accounted for the improved profitability.

Group's revenue and PBT increased by 5.90% and 70.68% year-on-year, respectively, attributed largely to the significant growth in Orgacids sales for both local and overseas markets. Orgacids sales reported 33.37% higher compared to the previous year, this has boosted the Group's PBT for the current year-to-date. The improved PBT was also due to higher gain on foreign exchange and reduction in product development expenditure.

B2. Review of performance of the operating segments of the Company and its principal subsidiaries for the current quarter and financial year-to-date

Revenue	Current Quarter Ended 30 September 2013 RM'000	Corresponding Quarter Ended 30 September 2012 RM'000	Current Year-To-Date Ended 30 September 2013 RM'000	Corresponding Year-To-Date Ended 30 September 2012 RM'000
Trading	4,556	3,969	12,627	12,200
Manufacturing	4,424	4,205	13,080	12,074
Total	8,980	8,174	25,707	24,274

B2. Review of performance of the operating segments of the Company and its principal subsidiaries for the current quarter and financial year-to-date (*Cont'd*)

A 14.79% increase in trading products sales for the current quarter compared to the previous year's corresponding quarter, mainly due to Companion animal products sales increased as a result of an increase in sales orders from Singapore as well as local market.

Manufacturing products sales up by 5.21% quarter-on-quarter, with Orgacids export sales increased outweighed the decrease in premixes product sales in the current quarter.

For year-on-year, trading products posted just a 3.50% increase in sales despite a significant increase of 60.00% in companion animal products sales, which was mainly impacted by the considerable decline in the sales of feed supplements and vaccines for the current year. While manufacturing products, sales increased by 8.33% compared to the previous year, attributed to the resilient sales performance of Orgacids in overseas as well as local market.

B3. Profit before taxation

Profit before taxation is arrived at after crediting/(charging):

	Current Quarter Ended 30 September 2013 RM'000	Corresponding Quarter Ended 30 September 2012 RM'000	Current Year-To-Date Ended 30 September 2013 RM'000	Corresponding Year-To-Date Ended 30 September 2012 RM'000
Interest income	25	24	67	72
Interest expense	(83)	(99)	(245)	(309)
Depreciation and Amortisation	(186)	(220)	(549)	(651)
Provision for and write off of receivables	(18)	-	(18)	-
Provision for and write off of inventories	(28)	(33)	(62)	(116)
Plant and equipment written off	-	(3)	-	(3)
Product development expenditure written off	-	(77)	-	(77)
Gain on disposal of plant and equipment	-	1	-	1
Gain on disposal of quoted shares	-	-	-	2
Gain/(loss) on foreign exchange				
- realised	75	(63)	157	26
- unrealised	52	125	62	119

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B4. Material changes in the Current Quarter's results compared to the results of the immediate Preceding Quarter

	Current Quarter Ended 30 September 2013 RM'000	Preceding Quarter Ended 30 June 2013 RM'000	Variance	
			RM'000	%
Revenue	8,980	8,553	427	4.99
PBT	1,227	770	457	59.35

Group's revenue increased by 4.99% for the current quarter compared to the preceding quarter, mainly attributed to higher product sales, particularly for feed supplements, veterinary pharmaceuticals and companion animal products. Orgacids sales were 9.79% lower compared to the preceding quarter, impact of this shortfall was cushioned by the increase of other feed supplements like TMQ 200 and Linko-S.

Group's PBT posted a 59.35% increase for the current quarter compared to the preceding quarter. This was mainly due to higher gain on foreign exchange, lower operating expenses and improved product sales for the current quarter.

B5. Prospects

The Board is of the opinion that the financial performance for the coming quarter is expected to be favourable in view of the existing Orgacids sales which continue to perform well. In addition, companion animal products business is expected to expand as pet foods sales are gaining momentum while sales for other livestock products are expected to increase as well with the year-end sales promotion campaign which will last for two months starting from 1 November 2013.

B6. Profit forecast and profit guarantee

No profit forecast or profit guarantee has been issued by the Group for the current quarter under review.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B7. Taxation

	Current Quarter Ended 30 September 2013 RM'000	Corresponding Quarter Ended 30 September 2012 RM'000	Current Year-To-Date Ended 30 September 2013 RM'000	Corresponding Year-To-Date Ended 30 September 2012 RM'000
<u>Income tax expense</u>				
Current financial year	213	146	458	447
Overprovision in previous financial year	(18)	-	(18)	(38)
	195	146	440	409
<u>Deferred tax expense</u>				
Current financial year	(10)	27	(1)	58
	(10)	27	(1)	58
Tax expense	185	173	439	467

The Company's wholly-owned subsidiary, Sunzen LifeSciences Sdn. Bhd. was awarded the BioNexus status incentive under the Promotion of Investment Act, 1986 by the Ministry of Finance, with the recommendation made by Malaysian Biotechnology Corporation Sdn. Bhd. on 23 July 2007. Accordingly, the subsidiary is granted 100% tax exemption from the statutory income derived from the production of in-feed anti bacterial products and supplements for animal health products for a period of 10 years commencing from 1 January 2010 to 31 December 2019.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B8. Status of Corporate Proposal

There was no other corporate proposal announced but not completed as at the date of this announcement.

Utilisation of IPO Proceeds

As at 30 September 2013, the status of utilisation of the gross proceeds of RM8 million raised from the public issue was as follows:

Purpose	Proposed utilisation RM'000	Actual utilisation RM'000	Intended timeframe for utilisation from the listing date* (Months)	Deviation		Explanation
				RM'000	%	
Research and development	4,770	4,383	36	-	-	Note ⁽¹⁾
Overseas expansion	1,000	1,000	48	-	-	-
Working capital	430	250	24	-	-	-
Estimated listing expenses	1,800	1,980	3	(180)	(10.00)	Note ⁽²⁾
Total	8,000	7,613				

Notes:

(1) Sunzen Biotech had announced to Bursa Securities on 17 September 2013 to further extend the utilisation period for the balance proceeds to 8 October 2014.

(2) The excess amount of listing expenses incurred during the implementation of Sunzen Biotech's listing exercise was adjusted to the Company's working capital.

* Sunzen Biotech was listed on 8 October 2008.

SUNZEN BIOTECH BERHAD
 (Company No: 680889-W)
 (Incorporated in Malaysia)

B9. Group borrowings and debt securities

The Group's borrowings as at 30 September 2013 were as follows:

	Secured RM'000	Unsecured RM'000	Total RM'000
<u>Short-term borrowings:-</u>			
Bills payable	1,188	-	1,188
Hire purchases	84	-	84
Term loans	548	-	548
	1,820	-	1,820
	Secured RM'000	Unsecured RM'000	Total RM'000
<u>Long-term borrowings:-</u>			
Hire purchases	28	-	28
Term loans	4,435	-	4,435
	4,463	-	4,463
Total	6,283	-	6,283

The above borrowings are denominated in Ringgit Malaysia.

B10. Material Litigation

As at the date of this announcement, neither the Company nor any of its subsidiaries is engaged in any material litigation and arbitration either as plaintiff or defendant, which has a material effect on the financial position of the Company or its subsidiaries and the Directors are not aware of any proceedings pending or threatened or of any facts likely to give rise to any proceedings which might materially and adversely affect the financial position or business of the Company or its subsidiaries.

B11. Dividend declared or recommended

An interim dividend of RM0.008 per ordinary share of RM0.10 each less income tax of 25% amounting to RM895,923 in respect of the financial year ending 31 December 2013 was declared on 9 September 2013 for payment on 8 October 2013.

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

B12. Earnings per share

Basic earnings per share is calculated by dividing the Group's profit after taxation attributable to owners of the Company for the period over the weighted average number of ordinary shares in issue excluding treasury shares during the financial period as follows:

	Current Quarter Ended 30 September 2013	Corresponding Quarter Ended 30 September 2012	Current Year-To -Date Ended 30 September 2013	Corresponding Year-To-Date Ended 30 September 2012
Group's profit after taxation attributable to owners of the Company (RM)	1,042,000	511,000	2,355,000	1,170,000
Weighted average number of ordinary shares in issue excluding treasury shares	149,320,500	149,380,500	149,320,500	149,380,500
Basic earnings per share (sen)	0.70	0.34	1.58	0.78

B13. Disclosure of Realised and Unrealised Profits or Losses

The breakdown of the retained profits of the Group at the end of the reporting period is presented in accordance with the directive issued by Bursa Securities and prepared in accordance with Guidance on Special Matter No. 1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Securities Listing Requirements, as issued by the Malaysian Institute of Accountants.

	Current Year-To-Date Ended 30 September 2013 RM'000	Corresponding Year-To-Date Ended 30 September 2012 RM'000
Total retained profits of the Group:-		
- Realised	18,723	18,026
- Unrealised	(438)	(551)
Total group retained profits as per consolidated financial statements	18,285	17,475

SUNZEN BIOTECH BERHAD
(Company No: 680889-W)
(Incorporated in Malaysia)

This quarterly report for the financial period ended 30 September 2013 has been seen and approved by the Board of Directors of Sunzen Biotech for release to Bursa Securities.

Date: 28 November 2013